Navigation Links
BUSM authors propose potential epigenetic mechanisms for improved cancer therapy
Date:2/19/2013

(Boston) A review article by researchers at Boston University School of Medicine (BUSM) proposes a new epigenetic hypothesis linked to tumor production and novel ideas about what causes progenitor cells to develop into cancer cells. Published in the February 2013 issue of Epigenomics, the article provides examples of how epigenetic drug treatments could be beneficial in treating cancers while also decreasing the likelihood of cancer relapse.

The article was written by researchers at the Boston University Cancer Center. Sibaji Sarkar, PhD, adjunct instructor of medicine at BUSM, is the article's corresponding author.

Cancer is a complex disease characterized by uncontrolled cell growth, division and invasion into other tissues. A 2004 review article published in Nature Medicine suggests that epigenetics, which is the phenomena whereby genetically identical cells express their genes differently resulting in different phenotypes and other factors play an important role in the formation of cancer originating from cancer stem cells.

Sarkar and colleagues propose that epigenetic processes, specifically DNA methylation, may trigger cancer progenitor cell formation from somatic cells in coordination with other cellular and environmental events. DNA methylation is a process that changes the DNA and causes genes to be silenced. In the absence of definitive proof of the existence of cancer stem cells, this hypothesis discusses a possible explanation for the formation and existence of cells that may develop into cancer. The researchers also explore why only some individuals develop cancer, despite identical genetic predispositions.

In cancer cells, the enzyme that maintains high levels of methylation in tumor suppressor genes is highly expressed, allowing uncontrolled growth. At the same time, many oncogenes, or genes with the potential to cause cancer, are activated and have lower levels of methylation. The apparent anomaly of the existence of both low and high rates of methylation could be explained with either the compartmentalization of these two processes and/or by the existence of both a methylation and demethylation system operating simultaneously at specific locations with the help of various accessory proteins.

The authors hypothesize the existence of both DNA methylating and demethylating enzymes in cells that regulate the methylation and demethylation process. Accessory proteins and/or small RNA factors could lead these enzymes to their sites of actions, resulting in some genes remaining methylated and others not methylated simultaneously within the same cellular environment. DNA sequences around the regions that are methylated and demethylated may also play role in these events. During drug treatments, the demethylating system dominates while the methylating enzyme is down-regulated, resulting in re-expression of silenced genes.

Recent studies have shown that epigenetic drug treatments prior to and with standard chemotherapy reduce the chance of cancer relapse.

"Progenitors are known to cause cancer relapse, and because epigenetic drugs can help destroy progenitor cells, these drugs could help reduce the chance of cancer relapse and improve the long-term outcomes of people with cancer," said Sarkar. "While our hypotheses are based on current knowledge, we are proposing important and exciting areas to be explored in the future."


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Jeffrey W. Olin, DO, authors study that describes symptoms and severity of fibromuscular dysplasia
2. Elsevier congratulates its British Medical Association award winning medical authors and editors
3. Authors of landmark study on infant mortality and electronic medical records receive Garfield Award
4. Dr. Marcelo Lancman, Medical Director of the Northeast Regional Epilepsy Group (NEREG) of New York and New Jersey Authors Book on New Epilepsy for Patients and Loved Ones
5. People can Achieve New Year’s Resolutions and Avoid Self-Sabotage -- so say Authors Tanya Chernova and Joanna Andros in UNDERMIND, from Indigo River Publishing
6. Holistic Family Doctor Authors Amazon Bestselling Book in Response to ObamaCare
7. IADR/AADR publish studies on severe early childhood caries - proposes new classification
8. Proposed testosterone testing of some female olympians challenged by Stanford scientists
9. EPA Proposes New Cuts on Levels of Soot in Air
10. Proposed drug may reverse Huntingtons disease symptoms
11. The hidden disorder: Unique treatment proposed for childrens neurological disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... is proud to partner with AquaShieldUSA, the country's oldest waterproof cast protector ... and medical supply stores, the largest selection of daily, night, weatherproof and waterproof ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... successful events, attracting medical professionals from around the globe who attended a week’s ... Opening Ceremonies Sunday, April 17 included the introduction of the 2016 ARRS Distinguished ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the ... of childhood mortality. This is particularly true in underdeveloped parts of Africa where clean ... of New England’s campus in Tangier, Morocco, will examine this global health issue and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Year at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is ... and safety. The Healthy Ageing division can include everything from antioxidants, lipids, proteins, ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing ... Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in July ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... announced the launch of a Phase 2 clinical study ... hearing in patients undergoing cochlear implantation (CI) surgery. This ... patients in Germany and ... the middle ear at the time of surgery. "Despite ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
(Date:4/26/2016)... Bayer AG has reported first-quarter ... and amortization. The earnings are the result of a ... Xarelto and Eylea, drugs Bayer is banking on to ... date was extended by four years this week to ... to reach a value of USD 1,147.1 billion ...
Breaking Medicine Technology: